Late-Stage Active Oncology Drug Developers | An Overview
June 22, 2024
Antibody Drug Conjugates (ADCs) are therapeutic entities with monoclonal antibody (mAb) backbone linked to cytotoxic drugs and are designed to...
Oncolytic Viruses (OVs) based therapies uses natural or genetically modified viruses to specifically infect and lyse cancer cells but does not...
Bispecific (bsAbs) & Multispecific antibodies are a diverse family of antibody constructs that recognize two or more epitopes. These candidates...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Articles in this...
109 Antibody Drug Conjugates Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
90 Antibody Drug Conjugates Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
90 Bi-specific Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
109 Bi-specific Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
Monoclonal Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
Monoclonal Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
NK is the abbreviation of Natural Killer, and its Chinese name is natural killer cell. Due to the pan-specific...
Read moreupdated.. easy.. precise... complete...
Presenting filtered comprehensive information. Gain more insights on emerging bio-business, frame strategies, grow faster & better connect with biological science community.
LEARN MORE »
Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.
Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.